Mechanistic Insights for Optimizing PSMA Radioligand Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32253231.
- Also identified by DOI 10.1158/1078-0432.CCR-20-0209.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important factor explaining variability in clinical results. The ability to visualize the target with theranostics provides unique mechanistic insights. Potential clinically applicable strategies to improve patient selection and optimize therapeutic efficacy are discussed.<i>See related article by Current et al., p. 2946</i>.
Medical subject headings
- Prostatic Neoplasms